Evidence map›Paper›PMID 27738907›Full record

ArticleJournal of endocrinological investigation2017

Secondary hyperparathyroidism prevalence and prognostic role in elderly males with heart failure.

G Loncar, B Bozic, N Cvetinovic, H-D Dungen, M Lainscak, S von Haehling, W Doehner, Z Radojicic, B Putnikovic, T Trippel and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Vitamin D deficiency and secondary hyperparathyroidism in adult Fontan patients.International journal of cardiology. Congenital heart disease · 2024
    Article
  5. Article
  6. Article
  7. Bone in heart failure.Journal of cachexia, sarcopenia and muscle · 2020
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Role of Vitamin D in Cardiovascular Diseases.Endocrinology and metabolism clinics of North America · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 3 countries.

G LoncarCardiology Department, Clinical Hospital Zvezdara, Dimitrija Tucovica 161, Belgrade, 11 000, Serbia. loncar_goran@yahoo.com.
B BozicInstitute for Medical Research, Military Medical Academy, Belgrade, Serbia.
N CvetinovicCardiology Department, Clinical Hospital Zvezdara, Dimitrija Tucovica 161, Belgrade, 11 000, Serbia.
H-D DungenDepartment of Cardiology, Campus Virchow, Charité Universitätsmedizin Berlin, Berlin, Germany.
M LainscakDepartments of Cardiology and Research and Education, General Hospital Celje, Celje, Slovenia.
S von HaehlingInnovative Clinical Trials, Department of Cardiology and Pneumology, University of Medicine Göttingen, Göttingen, Germany.
W DoehnerCenter for Stroke Research Berlin, Charite University Medical School, Berlin, Germany.
Z RadojicicInstitute for Statistics, Faculty of Organizational Sciences, University of Belgrade, Belgrade, Serbia.
B PutnikovicFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
T TrippelDepartment of Cardiology, Campus Virchow, Charité Universitätsmedizin Berlin, Berlin, Germany.
V PopovicFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
University of Belgrade · RSCharité - Universitätsmedizin Berlin · DECollege of Nursing in Celje · SIKliničko Bolnički Centar Zvezdara · RSMilitary Medical Academy · RSMSB Medical School Berlin · DEUniversity of Göttingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimEvaluation of secondary hyperparathyroidism (SHPT) and its prognostic impact on all-cause mortality in elderly males with heart failure (HF).

methodsSeventy three males (67 ± 7 years old) with systolic HF were included. Baseline PTH was measured. Patients were grouped according to PTH cut-off levels of 65 pg/ml (>65 pg/ml = SHPT vs. normal PTH). All-cause mortality was evaluated at 6-year follow-up.

resultsSHPT was diagnosed in 43 (59 %) patients. They were more severe compared to the patients with normal PTH regarding NYHA functional class (2.4 ± 0.5 vs. 2.1 ± 0.2, p = 0.001), quality of life score (34 ± 14 vs. 24 ± 12, p = 0.005), 6-min walking distance (378 ± 79 vs. 446 ± 73 m, p < 0.0001), left ventricular ejection fraction (27 ± 8 vs. 31 ± 7 %, p = 0.019), and NT-proBNP [2452 (3399) vs. 918 (1372) pg/ml, p < 0.0001]. No differences in age, vitamin D status, and renal function were noted between studied groups. A total of 41 (56 %) patients died within 6 years of follow-up. Kaplan-Meier survival analysis showed impaired long-term survival in patients with SHPT versus patients with normal PTH (p = 0.009). The rate of death was highest (75 %) in the group of patients with SHPT and NT-proBNP levels above median value (p = 0.003). Cox regression analysis demonstrated that NT-proBNP was the single independent predictor of all-cause mortality at 6-year follow-up [HR 3.698 (1.927-7.095), p < 0.0001].

conclusionSHPT was highly prevalent in elderly males with HF and was associated with impaired survival. HF patients with SHPT had more severe disease compared to the patients with normal serum PTH. Determination of serum PTH levels provided additional value to NT-proBNP for risk stratification in these patients.

Indexed as

Quality of LifeAgedBiomarkersHeart FailureHumansHyperparathyroidism, SecondaryMaleMiddle AgedPrevalencePrognosisROC CurveSerbiaSurvival RateBiomarkersHeart failureHyperparathyroidismMortalityPTH

Identifiers

PMID27738907
OpenAlexW2530644660

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.